Velcade (also known as PS-341 or Bortezomib) is a highly selective and reversible inhibitor
of the 26S proteasome and is approved for the treatment of patients with advanced multiple …

Cancer is a global health challenge that remains to be a field of extensive research aiming
to find new anticancer therapeutics. The 20S proteasome complex is one of the targets of …

Chemoresistance is the leading cause of limiting long-term treatment success in cancer
cells. Anticancer drugs usually kill cells through apoptosis induction and defects in this …

A series of novel dipeptidyl boronic acid compounds were designed, synthesized and
biologically investigated for the inhibition of the β5 subunit of 20S proteasome and several …

Glucose-regulated protein 78 kDa/binding immunoglobulin protein (GRP78/BIP) is a well-
known endoplasmic reticulum (ER) chaperone protein regulating ER stress by facilitating …

Bortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been
approved for the treatment of patients with relapsed and refractory multiple myeloma. A …

Searching the antitumor drug targets among proteasomes,“ubiquitous” enzyme systems,
may provide a new impulse to the antitumor drug discovery. In this study, changes in the …

Clinical trials with proteasome inhibitor Bortezomib (also named Velcade or PS-341) has
shown promising results for some cancers. However, other types of cancers including breast …

Inhibition of the proteasome offers many therapeutic possibilities in inflammation as well as
in neoplastic diseases. However, clinical use of proteasome inhibitors is limited by the …

The complexity of breast cancer includes many interacting biological processes that make it
difficult to find appropriate therapeutic treatments. Therefore, identifying potential diagnostic …